E4Relief (Response to Estetrol in Life Improvement for MEnopausal-associated Hot Flushes) (NCT02834312) | Clinical Trial Compass
CompletedPhase 2
E4Relief (Response to Estetrol in Life Improvement for MEnopausal-associated Hot Flushes)
Belgium260 participantsStarted 2016-05
Plain-language summary
This dose-finding study is being conducted to select the daily oral dose of estetrol (E4) for the treatment of vasomotor symptoms (VMS) in post-menopausal women.
Who can participate
Age range
40 Years – 65 Years
Sex
FEMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Women presenting at least 7 moderate to severe hot flushes/day or at least 50 moderate to severe hot flushes/week in the week preceding randomization.
* Body Mass Index (BMI) between 18.0 and 35.0 kg/m², inclusive.
* Post-menopausal status.
* Intact uterus.
* Negative pregnancy test.
* Good physical and mental health.
* Subject has provided signed and dated written informed consent before admission to the study.
* Subject is able to understand and comply with the protocol requirements, instructions, and protocol-stated restrictions.
Exclusion Criteria:
* Uterine disease or any medical conditions associated with an increase in endometrial thickness.
* Any history of malignancy with the exception of basal cell (excluded if within the prior 2 years) or squamous cell (excluded if within the prior one year) carcinoma of the skin. Any clinically significant findings at the breast examination and/or on mammography suspicious of breast malignancy that would require additional clinical testing to rule out breast cancer.
* Abnormal cervical Pap smear.
* Systolic blood pressure (BP) outside the range 90 to 140 mmHg, diastolic BP outside the range 60 to 90 mmHg, and/or heart rate outside the range 40 to 100 bpm.
* Any clinically significant abnormality identified on the screening 12-lead ECG.
* History of venous or arterial thromboembolic disease, history of known coagulopathy or abnormal coagulation factors.
* Diabetes mellitus with poor glycaemic control.
* Dys…
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Change in weekly frequency of moderate to severe VMS from baseline to week 4.
Timeframe: From baseline to week 4
2
Change in weekly frequency of moderate to severe VMS from baseline to week 12.
Timeframe: From baseline to week 12
3
Change in severity of moderate to severe VMS from baseline to week 4.
Timeframe: From baseline to week 4
4
Change in severity of moderate to severe VMS from baseline to week 12.